353 related articles for article (PubMed ID: 22249027)
1. Breast cancer stem cells.
Velasco-Velázquez MA; Homsi N; De La Fuente M; Pestell RG
Int J Biochem Cell Biol; 2012 Apr; 44(4):573-7. PubMed ID: 22249027
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
3. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
[TBL] [Abstract][Full Text] [Related]
5. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.
Paholak HJ; Stevers NO; Chen H; Burnett JP; He M; Korkaya H; McDermott SP; Deol Y; Clouthier SG; Luther T; Li Q; Wicha MS; Sun D
Biomaterials; 2016 Oct; 104():145-57. PubMed ID: 27450902
[TBL] [Abstract][Full Text] [Related]
6. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
[TBL] [Abstract][Full Text] [Related]
7. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
8. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer.
Liu M; Liu Y; Deng L; Wang D; He X; Zhou L; Wicha MS; Bai F; Liu S
Mol Cancer; 2018 Feb; 17(1):65. PubMed ID: 29471829
[TBL] [Abstract][Full Text] [Related]
10. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation.
Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL
Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell in breast cancer therapeutic resistance.
Bai X; Ni J; Beretov J; Graham P; Li Y
Cancer Treat Rev; 2018 Sep; 69():152-163. PubMed ID: 30029203
[TBL] [Abstract][Full Text] [Related]
12. Determining duration of HER2-targeted therapy using stem cell extinction models.
Riley L; Zhou H; Lange K; Sinsheimer JS; Sehl ME
PLoS One; 2012; 7(12):e46613. PubMed ID: 23284608
[TBL] [Abstract][Full Text] [Related]
13. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract][Full Text] [Related]
14. Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity.
Zhang R; Tu J; Liu S
Semin Cancer Biol; 2022 Jul; 82():11-25. PubMed ID: 33737107
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
16. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
Pavlopoulou A; Oktay Y; Vougas K; Louka M; Vorgias CE; Georgakilas AG
Cancer Lett; 2016 Oct; 380(2):485-493. PubMed ID: 27450721
[TBL] [Abstract][Full Text] [Related]
17. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram.
Sun T; Yang W; Toprani SM; Guo W; He L; DeLeo AB; Ferrone S; Zhang G; Wang E; Lin Z; Hu P; Wang X
Cell Commun Signal; 2020 Mar; 18(1):36. PubMed ID: 32138738
[TBL] [Abstract][Full Text] [Related]
18. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells.
Lee CH; Wu YT; Hsieh HC; Yu Y; Yu AL; Chang WW
Biochimie; 2014 Sep; 104():117-26. PubMed ID: 24950183
[TBL] [Abstract][Full Text] [Related]
20. Response to trastuzumab and investigation of expression profiles of matrix metalloproteinase-related proteins in primary breast cancer stem cells.
Koygun GK; Kars MD; Emsen A; Artac H; Aksoy F; Cakir M; Tavli L; Artac M
Clin Exp Med; 2021 Aug; 21(3):447-456. PubMed ID: 33471244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
